Almirall stock steadies on half-year revenue growth
Published on 09/02/2026 at 12:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Almirall stock (ISIN ES0157097017) is trading against a backdrop of half-year figures that show revenue growth in the latest reported period and a market value in the low-single-digit billions of euros. As of September 2, 2026, the shares are described as steady in recent market coverage, with the home-listing valuation still anchored to the latest completed session.
Half-year revenue still matters
Recent coverage published on September 1, 2026 said Almirall's latest half-year figures came after a second quarter in which revenue was slightly higher than in the first quarter. That same report put the company in the mid-cap range and linked the valuation to current prices and shares outstanding.
The investor angle is straightforward: the comparison between Q2 2026 and Q1 2026 is still the main operating clue, because the half-year set is the freshest reported base available in the current news flow.
What the latest quarter says
The same September 1, 2026 coverage said second-quarter 2026 revenue was slightly higher than in the first quarter, while the half-year period itself was described as generating total revenue in the hundreds of millions of euros. That gives investors at least two dated operating markers to frame the stock today.
Market context remains important too. The shares were described as trading on the Spanish home exchange, and the company was characterized as a mid-cap pharmaceutical name with a market capitalization in the low-single-digit billions of euros.
More on Almirall stock and filings
Open the company theme page for a deeper look at Almirall stock and related investor material.
Dermatology remains the core
Almirall remains a specialty pharmaceutical group, and the latest market note tied the half-year story to prescription dermatology medicines and other therapeutic areas in Europe and outside Europe. That product mix is why the revenue trend matters more than a single trading session.
The stock stays tied to the same simple question: can the company turn the latest half-year base into a cleaner second-half run-rate? The current figures give a dated starting point, not a forecast.
Home exchange valuation
On the Spanish home exchange, Almirall stock is framed as a mid-cap pharma name with a market capitalization in the low-single-digit billions of euros as of the latest completed trading session before September 1, 2026. That keeps the valuation readable even without a fresh price print in this call.
For investors, the combination of a mid-cap valuation, a revenue base in the hundreds of millions of euros for the half-year and a slightly stronger Q2 than Q1 is the key mix to watch into the next reporting date.
Almirall stock facts
- Company: Almirall, S.A.
- ISIN: ES0157097017
- Ticker: ALM
- Trading venue: BME
- Market capitalization: low-single-digit billions of euros, as of the latest completed trading session before September 1, 2026
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: not in a major DACH index
Almirall in one line
Almirall stock keeps its story centered on half-year revenue, second-quarter momentum and a mid-cap valuation on the Spanish home exchange.
